Journey Medical Corp

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. It s focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its sales and marketing model. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Journey Medical Corp reports revenue growth and profitability in Q1

Journey Medical Corp's Q1 2024 performance reflects revenue growth and profitability driven by key products and cost management.
The company's strengths lie in the success of DFD-29, financial stability, and strategic business development initiatives.
Challenges include maintaining market share, successful DFD-29 launch, and balancing new product pursuits with existing offerings.
Opportunities include leveraging DFD-29 for sustained profitability, exploring new product opportunities, and expanding global presence.

Journey Medical Corp (DERM) reports robust Q2 results and eyes FDA approval for growth

Journey Medical Corp (DERM) demonstrated strong revenue performance and cost management in Q2 2024, positioning for future growth.
The company's focus on innovation, IP protection, and financial discipline bodes well for long-term sustainability and profitability.
Despite challenges in a competitive market, Journey Medical Corp (DERM) remains optimistic about FDA approvals and revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corporation (NASDAQ:DERM ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Jules Abraham - IR, CORE IR Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Fortress Biotech

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a settlement agreement pertaining to the patents protecting QBREXZA®, the first and only prescription cloth towelette for the treatment of primary axillary hyperhidrosis, AMZEEQ®, the first and only topical minocycline product for the treatment of acne, and ZILXI®, the first and only topical minocycline product for the treatment of rosacea. Under terms of the paragraph IV settlement agreements, Padagis will not be allowed to launch generic versions of QBREXZA, AMZEEQ and ZILXI until August 15, 2030, July 1, 2031 and April 1, 2027, respectively.

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will present at the B. Riley Securities 22nd Annual Institutional Investor Conference, which is being held May 25-26, 2022 in Beverly Hills, California.

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

Journey Medical Corporation (NASDAQ:DERM ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jose Ibrahim - IR Claude Maraoui - Co-Founder, President and Chief Executive Officer Ernie De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Conference Call Participants Kalpit Patel - B. Riley Brandon Folkes - Cantor Fitzgerald Scott Henry - ROTH Capital Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) CEO Claude Maraoui on Q1 2022 Results - Earnings Call Transcript

Generated record revenue of $23.3 million for the first quarter of 2022

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities' Healthcare Equity Research team and will feature multiple programs from Fortress' diversified pipeline.

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Generated record net product revenues of $63.1 million for the full year 2021

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Company to hold conference call on March 23, 2022 at 4:30 p.m. ET Company to hold conference call on March 23, 2022 at 4:30 p.m. ET

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

Published Phase 2 clinical data show DFD-29 had approximately double the efficacy compared to Doxycycline capsules 40 mg on reducing total inflammatory lesions and IGA treatment success Published Phase 2 clinical data show DFD-29 had approximately double the efficacy compared to Doxycycline capsules 40 mg on reducing total inflammatory lesions and IGA treatment success

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it received notice from its exclusive licensing partner in Japan, Maruho Co., Ltd. (“Maruho”), that Japan's Ministry of Health, Labor and Welfare (“MHLW”) approved Rapifort® Wipes 2.5% (glycopyrronium tosylate hydrate) for the treatment of primary axillary hyperhidrosis. This approval triggers a milestone payment of $10 million to Journey Medical, $7.5 million of which will be paid to Dermira, Inc. (“Dermira”), a wholly-owned subsidiary of Eli Lilly and Company, pursuant to the terms of the Asset Purchase Agreement between Journey and Dermira, with net proceeds of $2.5 million to Journey. Pursuant to the terms of the agreement with Maruho, the milestone payment is due from Maruho within 30 days. Journey Medical acquired global rights to QBREXZA® from Dermira in 2021.

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

Generated record net revenues of $19.6 million for the third quarter of 2021

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per share, for gross proceeds of $35.2 million, before deducting underwriting discounts and offering expenses. All of the shares of common stock were offered by Journey Medical.

Journey Medical Corporation Announces Closing of Initial Public Offering

Journey Medical Corporation has filed proposed terms for a $35.2 million IPO. The firm develops and sells treatments for skin conditions.

Journey Medical Aims For $35 Million IPO

Amarin Corporation Plc

Bristol-Myers

Blackstone Group

Clovis Oncology

Intuitive Surgical

Johnson & Johnson

Kaleido Biosciences Inc

Eli Lilly

Medtronic

Roche Holding AG

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

Dermira Inc. (NASDAQ: DERM) shares made a handy gain to close out the week after it was announced that Eli Lilly and Co.

How This Dermira Acquisition Will Round Out Eli Lilly

Eli Lilly (NYSE: LLY) announced Friday it will acquire Dermira, Inc. (NASDAQ: DERM) for $18.75 per share, around $1.1 billion, in an all-cash transaction.

Eli Lilly Reports Deal To Buy Dermira For $1.1B

Eli Lilly & Co. LLY, +1.65% announced Friday a deal to buy medical dermatology company Dermira Inc.

Eli Lilly to buy Dermira in a deal valued at $1.1 billion

Agile Therapeutics

Air Industries Group

Microbot Medical

Cassava Sciences Inc

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

Dermira, Inc. (DERM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Dermira

As of late, it has definitely been a great time to be an investor in Dermira.

News for Journey Medical Corp Stock (DERM)